Rifaximin in cirrhosis: Is its microbiological spotless record under threat?

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Journal of Hepatology Pub Date : 2024-12-16 DOI:10.1016/j.jhep.2024.11.033

Cornelius Engelmann

{"title":"Rifaximin in cirrhosis: Is its microbiological spotless record under threat?","authors":"Cornelius Engelmann","doi":"10.1016/j.jhep.2024.11.033","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Background and context</h2>Patients with cirrhosis are particularly vulnerable to infections and other complications due to immune dysfunction and intestinal barrier impairment, leading to frequent antibiotic use and an associated rise in multidrug-resistant (MDR) organisms in this population.[1], [2], [3] Among the antimicrobials frequently employed, rifaximin, a gut-specific antibiotic with minimal systemic absorption, has gained prominence for the prevention of recurrent hepatic encephalopathy (HE).[4], [5], [6] Its</section></section><section><section><h2>Objectives, methods, and findings</h2>The recently published study in <em>Nature</em> by Turner <em>et al.</em><sup>13</sup> primarily aimed to uncover the mechanisms driving daptomycin resistance in vancomycin-resistant <em>Enterococcus faecium</em> (VREfm), focusing on unexplored genomic and phenotypic factors. Researchers analyzed a collection of 717 VREfm isolates from Australia, where they observed that 19.4% of the strains exhibited daptomycin resistance. To identify resistance mechanisms, the team screened the genomes of DAP-resistant and susceptible strains.</section></section><section><section><h2>Significance of findings</h2>This study highlights an emerging issue at the intersection of rifaximin use and the development of cross-resistance to a last resort antibiotic in VREfm via rpoB mutations. The findings present compelling experimental evidence about the potential mechanism but also raise significant unanswered questions, emphasizing the need for a nuanced evaluation of clinical implications and future directions in research.The association between rifaximin exposure and rpoB-mediated daptomycin resistance is</section></section><section><section><h2>Financial support</h2>The author did not receive any financial support to produce this manuscript.</section></section><section><section><h2>Conflict of interest</h2>The author of this study declares that they do not have any conflict of interest.Please refer to the accompanying ICMJE disclosure form for further details.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"16 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.11.033","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Background and context

Patients with cirrhosis are particularly vulnerable to infections and other complications due to immune dysfunction and intestinal barrier impairment, leading to frequent antibiotic use and an associated rise in multidrug-resistant (MDR) organisms in this population.[1], [2], [3] Among the antimicrobials frequently employed, rifaximin, a gut-specific antibiotic with minimal systemic absorption, has gained prominence for the prevention of recurrent hepatic encephalopathy (HE).[4], [5], [6] Its

Objectives, methods, and findings

The recently published study in Nature by Turner et al.¹³ primarily aimed to uncover the mechanisms driving daptomycin resistance in vancomycin-resistant Enterococcus faecium (VREfm), focusing on unexplored genomic and phenotypic factors. Researchers analyzed a collection of 717 VREfm isolates from Australia, where they observed that 19.4% of the strains exhibited daptomycin resistance. To identify resistance mechanisms, the team screened the genomes of DAP-resistant and susceptible strains.

Significance of findings

This study highlights an emerging issue at the intersection of rifaximin use and the development of cross-resistance to a last resort antibiotic in VREfm via rpoB mutations. The findings present compelling experimental evidence about the potential mechanism but also raise significant unanswered questions, emphasizing the need for a nuanced evaluation of clinical implications and future directions in research.The association between rifaximin exposure and rpoB-mediated daptomycin resistance is

Financial support

The author did not receive any financial support to produce this manuscript.

Conflict of interest

The author of this study declares that they do not have any conflict of interest.Please refer to the accompanying ICMJE disclosure form for further details.

查看原文本刊更多论文

利福昔明在肝硬化中的应用：它在微生物方面一尘不染的记录是否受到威胁？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.